Search
NOV-002
go.drugbank.com/drugs/DB05393InvestigationalNOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. … NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim.
Methylergometrine
go.drugbank.com/drugs/DB00353ApprovedInvestigational(Merck Index, 11th ed)
Synonyms: 9,10-Didehydro-N-[1-(hydroxymethyl)-propyl]-D-lysergamideGaliximab
go.drugbank.com/drugs/DB04901InvestigationalGaliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.
Eptotermin alfa
go.drugbank.com/drugs/DB11631ApprovedWithdrawnEptotermin alfa is an ingredient in the EMA-withdrawn product Osigraft.
R343
go.drugbank.com/drugs/DB06316InvestigationalR343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.
Synonyms: 2- {3- [4-(2,2-Difluoro-3 -oxo-3,4-dihydro-2H-benzo [1,4] oxazin-6-ylamino)5-fluoro-pyrimidin-2-ylamino]phenoxy}N-methyl-acetamideIproclozide
go.drugbank.com/drugs/DB09247ApprovedWithdrawnfatalities has resulted ultimately in the agent being discontinued. … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).
G207
go.drugbank.com/drugs/DB05827InvestigationalMediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.
ICA-105665
go.drugbank.com/drugs/DB06089InvestigationalIn addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain. … It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy.
Tricaprylin
go.drugbank.com/drugs/DB12176InvestigationalTricaprilin has been used in trials studying the supportive care and treatment of Alzheimer's Disease.
Categories: Compounds used in a research, industrial, or household settingBrigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026] … [A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.